Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite.
Bruning JM, Wang Y, Oltrabella F, Tian B, Kholodar SA, Liu H, Bhattacharya P, Guo S, Holton JM, Fletterick RJ, Jacobson MP, England PM
The dopamine metabolite DHI binds directly to Nurr1 and activates it in cell and zebrafish models. This finding identifies a natural mechanism for regulating Nurr1, which is relevant because NR4A2 mutations cause dopa-responsive dystonia in children.
- DHI covalently binds to Nurr1 at a non-canonical pocket.
- DHI stimulates Nurr1 activity and dopamine homeostasis genes.
- Results come from cell cultures and zebrafish models only.
- No human clinical data or patient outcomes are reported.
Minocycline Protects against Rotenone-Induced Neurotoxicity Correlating with Upregulation of Nurr1 in a Parkinson's Disease Rat Model.
Sun C, Wang Y, Mo M, Song C, Wang X, Chen S, Liu Y
Minocycline reduces brain inflammation and protects dopamine-producing neurons in rats with chemically induced Parkinson's disease. This protective effect correlates with increased levels of Nurr1, the protein encoded by the NR4A2 gene.
- Minocycline improves motor deficits in a rat model of Parkinson's disease.
- The drug increases Nurr1 and tyrosine hydroxylase levels in the substantia nigra.
- Minocycline suppresses reactive oxygen species and nitric oxide production.
- Nurr1 upregulation correlates with neuroprotection in this preclinical model.
A Nurr1 agonist amodiaquine attenuates inflammatory events and neurological deficits in a mouse model of intracerebral hemorrhage.
Kinoshita K, Matsumoto K, Kurauchi Y, Hisatsune A, Seki T, Katsuki H
Treating mice with a Nurr1 agonist reduces brain inflammation and improves motor function after a stroke-like injury. This study demonstrates that activating the NR4A2 protein can protect neural tissue in an acute injury model.
- The drug amodiaquine activates Nurr1 (NR4A2) in mouse brain cells.
- Treatment reduces inflammation around the injury site in mice.
- Mice show improved motor function after receiving the treatment.
- This is a preclinical study using an animal model of stroke.
Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition.
Hedya SA, Safar MM, Bahgat AK
Hydroxychloroquine improves motor symptoms in a rat model of Parkinson's disease by boosting Nurr1 expression and reducing inflammation. However, the drug also inhibits autophagy and increases markers of cell death, indicating significant safety concerns despite the behavioral improvements.
- Hydroxychloroquine increases Nurr1 levels in rat brains.
- The treatment reduces inflammation and improves motor coordination.
- The drug inhibits autophagy and raises apoptotic biomarkers.
- This is a preclinical study using rats, not humans.
- Safety risks from autophagy inhibition may outweigh benefits.
Genome sequencing identifies multiple deleterious variants in autism patients with more severe phenotypes.
Guo H, Duyzend MH, Coe BP, Baker C, Hoekzema K, Gerdts J, Turner TN, Zody MC, Beighley JS, Murali SC, Nelson BJ, University of Washington Center for Mendelian Genomics, Bamshad MJ, Nickerson DA, Bernier RA, Eichler EE
Genome sequencing identifies that carrying multiple genetic risk variants, including a de novo frameshift mutation in NR4A2, correlates with more severe cognitive impairment in children with autism spectrum disorder. This finding supports the diagnostic value of comprehensive genomic testing for identifying complex genetic causes of developmental delays.
- A de novo frameshift variant in NR4A2 was identified in an autism patient.
- Patients with multiple risk variants show significantly worse cognitive outcomes.
- Genome sequencing effectively detects pathogenic variants contributing to disease severity.
- The study highlights genetic heterogeneity within families affected by autism.
Alterations of NURR1 and Cytokines in the Peripheral Blood Mononuclear Cells: Combined Biomarkers for Parkinson's Disease.
Li T, Yang Z, Li S, Cheng C, Shen B, Le W
This study measures NURR1 and inflammatory markers in the blood of adults with Parkinson's disease to improve diagnostic accuracy. It confirms that NURR1 levels are lower and inflammation is higher in these patients compared to healthy controls or those with other neurological conditions.
- NURR1 gene expression is significantly decreased in the blood of Parkinson's patients.
- Inflammatory cytokines are elevated in Parkinson's patients compared to healthy controls.
- Combining NURR1 and cytokine measurements improves diagnostic accuracy for Parkinson's disease.
- The study focuses on using these markers as biomarkers rather than treatments.
Phenotypic Reprogramming of Striatal Neurons into Dopaminergic Neuron-like Cells in the Adult Mouse Brain.
Niu W, Zang T, Wang LL, Zou Y, Zhang CL
Researchers successfully converted existing striatal neurons into dopamine-producing neuron-like cells in adult mice using specific transcription factors and a drug. This demonstrates that neuronal identity can be reprogrammed in the adult brain, offering a potential future therapeutic strategy for neurological diseases involving dopamine loss.
- Adult mouse striatal neurons transform into dopamine-like cells in vivo.
- Reprogramming uses SOX2, NURR1, LMX1A, FOXA2, and valproic acid.
- New cells exhibit electrical properties of dopaminergic neurons.
- Study is preclinical; no human data or clinical trials reported.
Axin-2 knockdown promote mitochondrial biogenesis and dopaminergic neurogenesis by regulating Wnt/β-catenin signaling in rat model of Parkinson's disease.
Singh S, Mishra A, Mohanbhai SJ, Tiwari V, Chaturvedi RK, Khurana S, Shukla S
Reducing Axin-2 levels activates Wnt signaling, which protects dopamine neurons and promotes the growth of new ones in a rat model of Parkinson's disease. This mechanism improves motor behavior and mitochondrial function by upregulating key developmental genes including Nurr1.
- Knocking down Axin-2 boosts Wnt/beta-catenin signaling in rat brains.
- This intervention protects existing dopamine neurons from degeneration.
- It stimulates the birth of new dopamine neurons via Nurr1 and other genes.
- Mitochondrial health improves, reducing oxidative stress and cell death.
- Motor behaviors improve significantly in the treated parkinsonian rats.
HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, prevents ischemia-induced neuronal damage.
Loppi S, Kolosowska N, Kärkkäinen O, Korhonen P, Huuskonen M, Grubman A, Dhungana H, Wojciechowski S, Pomeshchik Y, Giordano M, Kagechika H, White A, Auriola S, Koistinaho J, Landreth G, Hanhineva K, Kanninen K, Malm T
The synthetic drug HX600 activates the Nurr1 protein to reduce brain inflammation and protect neurons from damage in mouse models of stroke. This study demonstrates that targeting the NR4A2/Nurr1 pathway can prevent neuroinflammation and motor deficits in an acute injury model.
- HX600 is a synthetic drug that activates the Nurr1/RXR protein complex.
- It reduces inflammatory markers in brain cells during stroke-like conditions.
- Treatment prevents neuron death and improves motor function in mice.
- The mechanism involves lowering specific pro-inflammatory metabolites in the brain.
A Zeb2-miR-200c loop controls midbrain dopaminergic neuron neurogenesis and migration.
Yang S, Toledo EM, Rosmaninho P, Peng C, Uhlén P, Castro DS, Arenas E
Overexpression of the transcription factor Zeb2 disrupts midbrain dopaminergic neuron development by reducing levels of NR4A2, PITX3, and CXCR4, leading to migration and differentiation defects. A regulatory loop between Zeb2 and miR-200c normally balances progenitor cell proliferation with neurogenesis in the developing midbrain.
- Zeb2 overexpression lowers NR4A2 levels in the developing ventral midbrain.
- Reduced NR4A2 causes defects in dopaminergic neuron migration and differentiation.
- Zeb2 is regulated by miR-200c to maintain progenitor cell balance.
- This study identifies Zeb2 as a critical regulator of midbrain development.
The lentiviral-mediated Nurr1 genetic engineering mesenchymal stem cells protect dopaminergic neurons in a rat model of Parkinson's disease.
Wang X, Zhuang W, Fu W, Wang X, Lv E, Li F, Zhou S, Rausch WD, Wang X
Genetically modified stem cells that overexpress Nurr1 protect dopamine-producing neurons and improve movement in rats with Parkinson's disease. This preclinical study demonstrates that delivering the Nurr1 gene via stem cells can reduce brain inflammation and restore neuronal markers in an animal model.
- Nurr1-modified stem cells survive and migrate within the rat brain after transplantation.
- Treatment significantly improves abnormal behaviors associated with Parkinson's disease in rats.
- The therapy increases dopamine neuron markers and reduces neuroinflammation.
- This is an animal study; human clinical evidence is not yet available.
Environmental Enrichment Prevents Transcriptional Disturbances Induced by Alpha-Synuclein Overexpression.
Wassouf Z, Hentrich T, Samer S, Rotermund C, Kahle PJ, Ehrlich I, Riess O, Casadei N, Schulze-Hentrich JM
An enriched environment prevents the gene activity disturbances caused by alpha-synuclein overexpression in mice. This protective effect involves sustaining the activation of immediate early genes, including Nurr1 (NR4A2).
- Enriched environments prevent transcriptional disturbances from alpha-synuclein in mice.
- Alpha-synuclein reduces levels of Nurr1 and other presynaptic proteins.
- Enrichment sustains activation of immediate early genes like Nurr1.
- This suggests environmental stimuli might mimic therapeutic benefits for neurodegeneration.
Ultrasound-Triggered Effects of the Microbubbles Coupled to GDNF Plasmid-Loaded PEGylated Liposomes in a Rat Model of Parkinson's Disease.
Yue P, Miao W, Gao L, Zhao X, Teng J
Ultrasound-triggered delivery of GDNF gene therapy reduces behavioral deficits and neuron loss in a rat model of Parkinson's disease. The treatment increases the expression of both GDNF and Nurr1, suggesting a potential mechanism for dopaminergic rescue.
- Study uses a rat Parkinson's model, not humans or NR4A2 syndrome patients.
- Treatment involves ultrasound-triggered gene delivery of GDNF plasmids.
- Results show improved behavior and preserved dopamine neurons in rats.
- Nurr1 expression increases alongside GDNF, linking to the parent's interest.
The Nurr1 Ligand,1,1-bis(3'-Indolyl)-1-(p-Chlorophenyl)Methane, Modulates Glial Reactivity and Is Neuroprotective in MPTP-Induced Parkinsonism.
Hammond SL, Popichak KA, Li X, Hunt LG, Richman EH, Damale PU, Chong EKP, Backos DS, Safe S, Tjalkens RB
A synthetic compound that activates the Nurr1 protein reduces brain inflammation and protects dopamine neurons in mice with Parkinson-like damage. This preclinical study suggests that targeting Nurr1 could potentially modify disease progression, but it does not provide evidence of safety or efficacy in humans.
- The drug C-DIM12 activates Nurr1 and crosses the blood-brain barrier effectively in mice.
- Treatment suppressed glial inflammation and prevented dopamine neuron loss in a Parkinson's mouse model.
- This is preclinical animal research with no human clinical data or trial results.
- Findings do not directly address NR4A2-related developmental syndromes or current treatments.
Kir6.2 Deficiency Promotes Mesencephalic Neural Precursor Cell Differentiation via Regulating miR-133b/GDNF in a Parkinson's Disease Mouse Model.
Zhou Y, Zhu J, Lv Y, Song C, Ding J, Xiao M, Lu M, Hu G
Removing the Kir6.2 gene in mice increases the production of dopamine-producing neurons by boosting GDNF levels, which helps repair damage caused by Parkinson's-like toxins. This suggests that blocking Kir6.2 could potentially stimulate the brain's natural ability to replace lost dopamine cells.
- Kir6.2 deficiency boosts differentiation of precursors into dopamine neurons in mice.
- The mechanism involves inhibiting miR-133b, which normally suppresses the protective factor GDNF.
- Blocking Kir6.2 activates an endogenous self-repair process for damaged dopamine neurons.
- This is a preclinical mouse study with no human clinical data or trials.
Whole transcriptome profiling of Late-Onset Alzheimer's Disease patients provides insights into the molecular changes involved in the disease.
Annese A, Manzari C, Lionetti C, Picardi E, Horner DS, Chiara M, Caratozzolo MF, Tullo A, Fosso B, Pesole G, D'Erchia AM
This study identifies miR-184 as a regulator of NR4A2 in the human hippocampus, showing that their expression levels are inversely correlated in Alzheimer's disease. The findings provide molecular evidence that NR4A2 is involved in cognitive functions and memory processes within the human brain.
- miR-184 directly targets the NR4A2 gene in the human hippocampus.
- NR4A2 expression decreases as miR-184 levels increase in Alzheimer's patients.
- The study confirms NR4A2's role in cognitive function and long-term memory.
- Transcriptome profiling reveals specific deregulated genes in late-onset Alzheimer's disease.
miR-34b/c Regulates Wnt1 and Enhances Mesencephalic Dopaminergic Neuron Differentiation.
De Gregorio R, Pulcrano S, De Sanctis C, Volpicelli F, Guatteo E, von Oerthel L, Latagliata EC, Esposito R, Piscitelli RM, Perrone-Capano C, Costa V, Greco D, Puglisi-Allegra S, Smidt MP, di Porzio U, Caiazzo M, Mercuri NB, Li M, Bellenchi GC
This study shows that miR-34b/c enhances the creation of dopaminergic neurons from skin cells when combined with NURR1, a protein related to NR4A2. The resulting cells function like real brain neurons by producing dopamine and firing electrical signals.
- miR-34b/c boosts the conversion of skin cells into dopamine-producing neurons.
- Combining miR-34b/c with NURR1 doubles the yield of these specialized cells.
- The generated cells exhibit natural dopamine synthesis and electrical activity.
- This offers a potential method for generating patient-specific dopaminergic neurons in the lab.
Ultrasound-triggered effects of the microbubbles coupled to GDNF- and Nurr1-loaded PEGylated liposomes in a rat model of Parkinson's disease.
Yue P, Gao L, Wang X, Ding X, Teng J
Ultrasound-triggered delivery of GDNF and Nurr1 via liposomes reduces motor deficits and preserves dopamine neurons in a rat model of Parkinson's disease. The combined gene therapy approach proves more effective than single-gene treatments in this preclinical animal study.
- Study uses rats, not humans, limiting direct clinical applicability.
- Combining GDNF and Nurr1 genes outperforms single-gene delivery.
- Ultrasound helps deliver therapy across the blood-brain barrier.
- Results show reduced motor impairment and neuron loss in animals.
Nurr1 promotes neurogenesis of dopaminergic neuron and represses inflammatory factors in the transwell coculture system of neural stem cells and microglia.
Chen XX, Qian Y, Wang XP, Tang ZW, Xu JT, Lin H, Yang ZY, Song XB, Lu D, Guo JZ, Bian LG, Li Y, Zhou L, Deng XL
Overexpressing Nurr1 in neural stem cells promotes their differentiation into dopamine-producing neurons and reduces inflammation from surrounding immune cells. This suggests that modifying stem cells with Nurr1 could improve survival and function if used for cell replacement therapies.
- Nurr1 pushes stem cells to become dopamine neurons instead of glial cells.
- Nurr1 suppresses inflammatory signals from microglia that harm neurons.
- The study uses a lab coculture system, not living animals or humans.
- Results support the theoretical basis for Nurr1-enhanced stem cell transplants.
Cilostazol Mediated Nurr1 and Autophagy Enhancement: Neuroprotective Activity in Rat Rotenone PD Model.
Hedya SA, Safar MM, Bahgat AK
Cilostazol protects dopaminergic neurons and improves motor function in rats with Parkinson's disease by increasing Nurr1 levels. The drug also reduces inflammation and cell death while enhancing cellular cleanup processes through related molecular pathways.
- Cilostazol upregulates Nurr1, preserving dopamine neuron integrity in rat models.
- Treatment improves motor performance and increases striatal tyrosine hydroxylase levels.
- The drug reduces inflammation by inhibiting NF-kappa B signaling pathways.
- Cilostazol prevents cell death by suppressing apoptotic biomarkers like caspase-3.
- Enhanced autophagy occurs via Sirtuin 1 activation, aiding cellular health.
Neuroprotective effect of olfactory ensheathing cells co-transfected with Nurr1 and Ngn2 in both in vitro and in vivo models of Parkinson's disease.
Liu Q, Qin Q, Sun H, Zhong D, An R, Tian Y, Chen H, Jin J, Wang H, Li G
Transplanting olfactory ensheathing cells engineered to produce Nurr1 and Ngn2 reduces cell death and improves movement in rats with Parkinson's disease. This approach works by activating a specific growth factor pathway that protects neurons from damage.
- Engineered cells protect dopamine neurons from oxidative stress and apoptosis in rat models.
- Transplantation significantly improves motor behavior deficits in Parkinsonian rats.
- The protective effect relies on the upregulation of the neurotrophic factor-TrkB pathway.
- This is preclinical animal research with no human clinical data.
Creating a graft-friendly environment for stem cells in diseased brains.
Tsai RY
Engineering astrocytes to overexpress Nurr1 and Foxa2 improves the survival and integration of transplanted stem cells in a rat model of Parkinson's disease. This approach creates a supportive environment that enhances therapeutic outcomes for neural grafts.
- Engineered astrocytes improve stem cell survival in diseased brains.
- Nurr1 and Foxa2 overexpression drives this protective effect.
- The study uses a rat model of Parkinson's disease.
- Results suggest potential for restorative treatments via modified astrocytes.
Cografting astrocytes improves cell therapeutic outcomes in a Parkinson's disease model.
Song JJ, Oh SM, Kwon OC, Wulansari N, Lee HS, Chang MY, Lee E, Sun W, Lee SE, Chang S, An H, Lee CJ, Lee SH
Adding midbrain astrocytes to neural progenitor cell transplants significantly improves neuron survival and therapeutic outcomes in a rat model of Parkinson's disease. Engineering these astrocytes with Nurr1 and Foxa2 further enhances their neuroprotective effects, suggesting a potential strategy to overcome the hostile brain environment that currently limits cell therapies.
- Cografting midbrain astrocytes boosts neural progenitor cell engraftment in Parkinson's rats for over six months.
- Engineering astrocytes with Nurr1 and Foxa2 enhances their neuroprotective properties.
- This approach addresses the hostile host brain environment that limits current cell therapies.
- The study uses a rat model, not human patients or NR4A2-specific cohorts.
Efficient Generation of Dopamine Neurons by Synthetic Transcription Factor mRNAs.
Kim SM, Lim MS, Lee EH, Jung SJ, Chung HY, Kim CH, Park CH
Researchers successfully convert rat brain precursor cells into functional dopamine neurons using synthetic mRNA for Nurr1 and FoxA2, avoiding the genetic risks associated with viral gene delivery. This method produces safe, transformation-free cells that exhibit key biochemical and electrical properties of dopamine neurons in a laboratory setting.
- Synthetic mRNA delivers Nurr1 and FoxA2 to create dopamine neurons without viral vectors.
- The approach avoids chromosomal anomalies linked to traditional DNA or virus-based gene delivery.
- Derived cells show correct biochemical, electrical, and functional traits of dopamine neurons in vitro.
- Small molecules and timing adjustments improve the efficiency of neuron generation.
- This technique offers a potential pathway for clinical-grade cell sources for Parkinson's disease.
Modulatory Role of Nurr1 Activation and Thrombin Inhibition in the Neuroprotective Effects of Dabigatran Etexilate in Rotenone-Induced Parkinson's Disease in Rats.
Kandil EA, Sayed RH, Ahmed LA, Abd El Fattah MA, El-Sayeh BM
Dabigatran protects dopaminergic neurons in a rat model of Parkinson's disease by inhibiting thrombin and activating Nurr1, which restores dopamine levels and reduces inflammation. This preclinical study demonstrates that the drug's neuroprotective effects rely on these specific molecular pathways.
- Dabigatran restores dopamine levels and motor function in rats with Parkinson-like symptoms.
- The drug activates Nurr1, boosting genes essential for dopaminergic neuron survival.
- Thrombin inhibition by dabigatran reduces neuroinflammation in the substantia nigra.
- This is an animal study; human clinical evidence is not provided.
Selective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits.
Larson ME, Greimel SJ, Amar F, LaCroix M, Boyle G, Sherman MA, Schley H, Miel C, Schneider JA, Kayed R, Benfenati F, Lee MK, Bennett DA, Lesné SE
Oligomeric alpha-synuclein reduces synapsin protein levels by suppressing the transcription factors Nurr1 (NR4A2) and CREB, which directly control synapsin gene expression. This mechanism links pathological alpha-synuclein accumulation to memory deficits through the downregulation of NR4A2-dependent pathways.
- Alpha-synuclein oligomers lower synapsin-I and synapsin-II protein abundance in neurons.
- This reduction occurs via decreased activity of Nurr1 (NR4A2) and CREB transcription factors.
- Synapsin gene expression drops when Nurr1 and CREB promoter activity is suppressed.
- Endogenous alpha-synuclein oligomers impair memory by selectively reducing synapsin levels.
Association of polymorphisms and reduced expression levels of the NR4A2 gene with Parkinson's disease in a Mexican population.
Ruiz-Sánchez E, Yescas P, Rodríguez-Violante M, Martínez-Rodríguez N, Díaz-López JN, Ochoa A, Valdes-Rojas SS, Magos-Rodríguez D, Rojas-Castañeda JC, Cervantes-Arriaga A, Canizales-Quinteros S, Rojas P
This study links specific genetic variations in the NR4A2 gene to an increased risk of Parkinson's disease and lower gene expression levels in blood cells. It confirms that certain polymorphisms reduce NR4A2 activity, providing human genetic evidence of how this gene influences neurological health.
- Specific NR4A2 polymorphisms increase Parkinson's disease risk in the studied population.
- NR4A2 gene expression is significantly lower in patients with Parkinson's disease.
- A specific haplotype combines risk alleles and correlates with reduced gene expression.
- This provides human genetic data on NR4A2 function, relevant to understanding its role.
Dual delivery of siRNA and plasmid DNA using mesoporous silica nanoparticles to differentiate induced pluripotent stem cells into dopaminergic neurons.
Chang JH, Tsai PH, Chen W, Chiou SH, Mou CY
Researchers successfully used non-viral nanoparticles to deliver genetic instructions that converted stem cells into dopamine-producing neurons in a laboratory setting. This approach significantly increased the production of functional dopaminergic neurons compared to using genetic material alone.
- Mesoporous silica nanoparticles delivered Nurr1 DNA and Rex1 siRNA to stem cells.
- Co-delivery tripled Nurr1 gene expression compared to plasmid delivery alone.
- Nearly 90% of treated cells became tyrosine hydroxylase-expressing neurons.
- Cells released measurable amounts of dopamine, indicating functional maturity.
- The study demonstrates a non-viral method for generating dopaminergic neurons in vitro.
Region Specific Effects of Aging and the Nurr1-Null Heterozygous Genotype on Dopamine Neurotransmission.
Kummari E, Guo-Ross S, Eells JB
Mice with one non-functional copy of the Nurr1 gene show reduced dopamine levels in specific brain regions as they age, particularly affecting the ventral striatum more than the dorsal striatum. While these mice do not show baseline movement differences, they exhibit increased activity after stress, suggesting that aging and this genetic change interact to impact dopamine systems differently across brain areas.
- Aging combined with one non-functional Nurr1 gene lowers dopamine in the ventral striatum.
- Dorsal striatum dopamine levels remain stable despite aging and the genetic change.
- Mice show normal baseline movement but increased activity after stress.
- The ventral dopamine system is more vulnerable to aging than the dorsal system.
- Results suggest genetic background or housing may influence these outcomes.
Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
Spathis AD, Asvos X, Ziavra D, Karampelas T, Topouzis S, Cournia Z, Qing X, Alexakos P, Smits LM, Dalla C, Rideout HJ, Schwamborn JC, Tamvakopoulos C, Fokas D, Vassilatis DK
A drug candidate named BRF110 activates the Nurr1:RXRα pathway to protect dopamine-producing neurons and improve symptoms in animal models and human stem cell-derived neurons. This approach prevents neuronal death and restores dopamine levels without causing the movement side effects seen with current Parkinson's treatments.
- BRF110 protects dopamine neurons from damage caused by toxins and genetic mutations.
- The drug increases key enzymes needed for dopamine production in living models.
- It improves symptoms in Parkinson's models without inducing dyskinesias over time.
- Testing occurred in mice and human stem-cell neurons, not in people.
Possible genes responsible for developmental delay observed in patients with rare 2q23q24 microdeletion syndrome: Literature review and description of an additional patient.
Shimojima K, Okamoto N, Yamamoto T
This study identifies NR4A2 as a candidate gene within a larger chromosomal deletion region associated with severe developmental delay and language impairment in humans. It supports the link between loss of NR4A2 function and neurodevelopmental phenotypes, specifically highlighting that combined deletions involving KCNJ3 and GPD2 may worsen outcomes.
- NR4A2 lies within a 2q23q24 microdeletion region linked to developmental delay.
- A new patient with an extended deletion shows severe developmental delay.
- KCNJ3, not GALNT13, likely drives behavioral abnormalities in this syndrome.
- Combined loss of KCNJ3 and GPD2 correlates with more severe delays.
In vitro generation of mature midbrain-type dopamine neurons by adjusting exogenous Nurr1 and Foxa2 expressions to their physiologic patterns.
Kim T, Song JJ, Puspita L, Valiulahi P, Shim JW, Lee SH
Researchers demonstrate that precisely controlling the timing and levels of Nurr1 and Foxa2 genes allows stem cells to mature into functional midbrain dopamine neurons. This method overcomes previous limitations where simple gene overexpression failed to produce stable, fully developed neurons suitable for transplantation.
- Controlling Nurr1 and Foxa2 expression timing improves neuron maturity.
- Simple overexpression fails to create stable, long-lasting dopamine neurons.
- The technique generates midbrain-type dopamine neurons from stem cells.
- This approach supports future cellular therapies for Parkinson's disease.
Regulation of human GDNF gene expression in nigral dopaminergic neurons using a new doxycycline-regulated NTS-polyplex nanoparticle system.
Espadas-Alvarez AJ, Bannon MJ, Orozco-Barrios CE, Escobedo-Sanchez L, Ayala-Davila J, Reyes-Corona D, Soto-Rodriguez G, Escamilla-Rivera V, De Vizcaya-Ruiz A, Eugenia Gutierrez-Castillo M, Padilla-Viveros A, Martinez-Fong D
Researchers developed a nanoparticle delivery system that allows precise, on-demand control of GDNF protein production in dopaminergic neurons using doxycycline. This technology prevents the harmful effects of sustained high GDNF levels by silencing expression when the drug is withdrawn.
- The system uses nanoparticles to deliver genes specifically to dopaminergic neurons.
- Doxycycline activates GDNF production, while stopping the drug turns it off.
- This approach aims to balance therapeutic benefit with safety in Parkinson's models.
- The study demonstrates proof-of-concept in rat models of Parkinson's disease.
Identification of NURR1 (Exon 4) and FOXA1 (Exon 3) Haplotypes Associated with mRNA Expression Levels in Peripheral Blood Lymphocytes of Parkinson's Patients in Small Indian Population.
Tippabathani J, Nellore J, Radhakrishnan V, Banik S, Kapoor S
This study measures NURR1 and FOXA1 gene activity in the blood of Parkinson's patients, finding significantly reduced levels compared to healthy individuals. It identifies specific genetic variations (haplotypes) in these genes that correlate with expression levels, suggesting potential peripheral markers for disease.
- NURR1 and FOXA1 mRNA levels are significantly lower in Parkinson's patients than in healthy controls.
- The study analyzes a small Indian cohort of 30 patients and 30 matched healthy individuals.
- Genetic variations in NURR1 exon 4 and FOXA1 exon 3 are identified in both groups.
- Expression differences vary by gender, with males showing greater reduction in NURR1.
- Findings suggest these blood markers could aid in early Parkinson's detection.
Nurr1 overexpression exerts neuroprotective and anti-inflammatory roles via down-regulating CCL2 expression in both in vivo and in vitro Parkinson's disease models.
Liu W, Gao Y, Chang N
Overexpressing Nurr1 reduces inflammation and protects dopaminergic neurons in mouse models of Parkinson's disease by lowering levels of the inflammatory protein CCL2. This mechanism suggests that restoring Nurr1 function could theoretically mitigate neurodegeneration, though this has only been demonstrated in preclinical animal and cell studies.
- Nurr1 levels are low and CCL2 levels are high in Parkinson's patients and mice.
- Increasing Nurr1 reduces inflammation and protects neurons from damage in lab models.
- The protective effect works by suppressing the inflammatory marker CCL2.
- Results come exclusively from mouse and cell culture experiments, not human trials.
Admixing of MPTP-Resistant and Susceptible Mice Strains Augments Nigrostriatal Neuronal Correlates to Resist MPTP-Induced Neurodegeneration.
Vidyadhara DJ, Yarreiphang H, Raju TR, Alladi PA
Crossbreeding MPTP-resistant and susceptible mouse strains completely prevents the loss of dopaminergic neurons caused by the toxin. This protection correlates with higher baseline levels of Nurr1 (NR4A2), increased striatal GDNF, and reduced apoptosis markers in the resistant crossbred mice. The study suggests that genetic admixture can enhance resilience against neurodegeneration through these specific molecular pathways.
- Crossbred mice show no dopaminergic neuron loss after MPTP exposure.
- Resilience links to higher Nurr1, TH, and PitX3 expression levels.
- Elevated striatal GDNF likely compensates for neuronal stress in resistant strains.
- Reduced caspase-3 activity prevents apoptosis in the protected crossbreds.
- Findings model how genetic diversity might influence Parkinson's susceptibility.
The pharmacological stimulation of Nurr1 improves cognitive functions via enhancement of adult hippocampal neurogenesis.
Kim JI, Jeon SG, Kim KA, Kim YJ, Song EJ, Choi J, Ahn KJ, Kim CJ, Chung HY, Moon M, Chung H
Activating the Nurr1 protein with a specific drug increases the growth of new brain cells and improves memory in mice. This suggests that targeting Nurr1 could potentially treat cognitive issues, but this benefit has only been observed in animal models so far.
- Nurr1 activation boosts the creation of new neurons in the adult mouse hippocampus.
- The drug amodiaquine improved short- and long-term memory in treated mice.
- The mechanism involves increased cell proliferation and differentiation of neural precursors.
- This is preclinical evidence from mice, not human clinical data.
Rare Inherited and De Novo CNVs Reveal Complex Contributions to ASD Risk in Multiplex Families.
Leppa VM, Kravitz SN, Martin CL, Andrieux J, Le Caignec C, Martin-Coignard D, DyBuncio C, Sanders SJ, Lowe JK, Cantor RM, Geschwind DH
This study identifies a rare genetic risk locus for autism and language delay at chromosomal region 2q24, which contains the NR4A2 gene. It confirms that NR4A2 is implicated in neurodevelopmental conditions involving language impairment.
- The study links the 2q24 region, including NR4A2, to autism and language delay risk.
- Researchers analyzed over 1,500 families with multiple affected children to find genetic patterns.
- Inherited copy-number variants contribute significantly to autism risk in multiplex families.
- Genetic architecture in families with multiple affected members differs from those with one child.
Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease.
Gorelenkova Miller O, Behring JB, Siedlak SL, Jiang S, Matsui R, Bachschmid MM, Zhu X, Mieyal JJ
Elevated levels of the protein Glutaredoxin-1 drive microglial inflammation and dopaminergic neuron loss in mouse models of Parkinson's disease. This study identifies a genetic link between increased GLRX copy numbers and earlier Parkinson's onset in human patients, suggesting that redox imbalance contributes to neurodegeneration.
- High Glutaredoxin-1 activates microglia, causing inflammation and dopaminergic neuron death.
- Increased GLRX gene copies correlate with earlier Parkinson's disease onset in humans.
- Mouse models show Grx1 upregulation leads to dopamine loss, especially with insulin resistance.
- Grx1 induction relies on the Nurr1/NF-κB signaling axis in microglial cells.
Daphnane Diterpenes from Daphne genkwa Activate Nurr1 and Have a Neuroprotective Effect in an Animal Model of Parkinson's Disease.
Han BS, Kim KS, Kim YJ, Jung HY, Kang YM, Lee KS, Sohn MJ, Kim CH, Kim KS, Kim WG
Two natural compounds from the Daphne genkwa plant activate Nurr1 and protect dopaminergic neurons in a rat model of Parkinson's disease. These compounds improve motor behavior and reduce brain inflammation in animals with induced neuronal damage.
- Compounds genkwanine N and yuanhuacin activate the Nurr1 receptor in cell assays.
- They protect dopaminergic neurons from death caused by toxins in laboratory settings.
- Treatment improves motor deficits and reduces neuroinflammation in Parkinson's disease rats.
- The study identifies these natural compounds as potential leads for future drug development.